The Importance of Implementation Strategy in Scaling Up Xpert MTB/RIF for Diagnosis of Tuberculosis in the Indian Health-Care System: A Transmission Model

English version České info

Background:
India has announced a goal of universal access to quality tuberculosis (TB) diagnosis and treatment. A number of novel diagnostics could help meet this important goal. The rollout of one such diagnostic, Xpert MTB/RIF (Xpert) is being considered, but if Xpert is used mainly for people with HIV or high risk of multidrug-resistant TB (MDR-TB) in the public sector, population-level impact may be limited.

Methods and Findings:
We developed a model of TB transmission, care-seeking behavior, and diagnostic/treatment practices in India and explored the impact of six different rollout strategies. Providing Xpert to 40% of public-sector patients with HIV or prior TB treatment (similar to current national strategy) reduced TB incidence by 0.2% (95% uncertainty range [UR]: −1.4%, 1.7%) and MDR-TB incidence by 2.4% (95% UR: −5.2%, 9.1%) relative to existing practice but required 2,500 additional MDR-TB treatments and 60 four-module GeneXpert systems at maximum capacity. Further including 20% of unselected symptomatic individuals in the public sector required 700 systems and reduced incidence by 2.1% (95% UR: 0.5%, 3.9%); a similar approach involving qualified private providers (providers who have received at least some training in allopathic or non-allopathic medicine) reduced incidence by 6.0% (95% UR: 3.9%, 7.9%) with similar resource outlay, but only if high treatment success was assured. Engaging 20% of all private-sector providers (qualified and informal [providers with no formal medical training]) had the greatest impact (14.1% reduction, 95% UR: 10.6%, 16.9%), but required >2,200 systems and reliable treatment referral. Improving referrals from informal providers for smear-based diagnosis in the public sector (without Xpert rollout) had substantially greater impact (6.3% reduction) than Xpert scale-up within the public sector. These findings are subject to substantial uncertainty regarding private-sector treatment patterns, patient care-seeking behavior, symptoms, and infectiousness over time; these uncertainties should be addressed by future research.

Conclusions:
The impact of new diagnostics for TB control in India depends on implementation within the complex, fragmented health-care system. Transformative strategies will require private/informal-sector engagement, adequate referral systems, improved treatment quality, and substantial resources.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Importance of Implementation Strategy in Scaling Up Xpert MTB/RIF for Diagnosis of Tuberculosis in the Indian Health-Care System: A Transmission Model. PLoS Med 11(7): e32767. doi:10.1371/journal.pmed.1001674
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001674

Souhrn

Zdroje

1. World Health Organization (2012) Global tuberculosis report 2012. Geneva: World Health Organization.

2. UdwadiaZF, AmaleRA, AjbaniKK, RodriguesC (2012) Totally drug-resistant tuberculosis in India. Clin Infect Dis 54: 579–581.

3. UdwadiaZF, PintoLM, UplekarMW (2010) Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades? PLoS ONE 5: e12023.

4. UplekarM, JuvekarS, MorankarS, RanganS, NunnP (1998) Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis 2: 324–329.

5. DowdyDW, SteingartKR, PaiM (2011) Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis. PLoS Med 8: e1001074.

6. JarosławskiS, PaiM (2012) Why are inaccurate tuberculosis serological tests widely used in the Indian private healthcare sector? A root-cause analysis. J Epidemiol Glob Health 2: 39–50.

7. WellsWA, GeCF, PatelN, OhT, GardinerE, et al. (2011) Size and usage patterns of private TB drug markets in the high burden countries. PLoS ONE 6: e18964.

8. SatyanarayanaS, NairSA, ChadhaSS, ShivashankarR, SharmaG, et al. (2011) From where are tuberculosis patients accessing treatment in India? Results from a cross-sectional community based survey of 30 districts. PLoS ONE 6: e24160.

9. HazarikaI (2011) Role of private sector in providing tuberculosis care: evidence from a population-based survey in India. J Glob Infect Dis 3: 19–24.

10. DyeC (2012) The potential impact of new diagnostic tests on tuberculosis epidemics. Indian J Med Res 135: 737–744.

11. DasJ, HollaA, DasV, MohananM, TabakD, et al. (2012) In urban and rural India, a standardized patient study showed low levels of provider training and huge quality gaps. Health Aff (Millwood) 31: 2774–2784.

12. KapoorSK, RamanAV, SachdevaKS, SatyanarayanaS (2012) How did the TB patients reach DOTS services in Delhi? A study of patient treatment seeking behavior. PLoS ONE 7: e42458.

13. SudhaG, NirupaC, RajasakthivelM, SivasusbramanianS, SundaramV, et al. (2003) Factors influencing the care-seeking behaviour of chest symptomatics: a community-based study involving rural and urban population in Tamil Nadu, South India. Trop Med Int Health 8: 336–341.

14. SreeramareddyCT, QinZZ, SatyanarayanaS, SubbaramanR, PaiM (2014) Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. Int J Tuberc Lung Dis 18: 255–266.

15. World Health Organization Country Office for India (2014) Standards for TB care in India. New Delhi: World Health Organization. Available: http://www.tbcindia.nic.in/pdfs/STCI%20Book_Final%20%20060514.pdf.

16. SachdevaKSK, KumarAA, DewanPP, KumarAA, SatyanarayanaSS (2012) New vision for Revised National Tuberculosis Control Programme (RNTCP): universal access—“reaching the un-reached”. Indian J Med Res 135: 690–694.

17. SteingartKR, HenryM, NgV, HopewellPC, RamsayA, et al. (2006) Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 6: 570–581.

18. StallN, RubinT, MichaelJS, MathaiD, AbrahamOC, et al. (2011) Does solid culture for tuberculosis influence clinical decision making in India? Int J Tuberc Lung Dis 15: 641–646.

19. World Health Organization (2011) Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement. Geneva: World Health Organization.

20. PaiM (2013) Promoting affordable and quality tuberculosis testing in India. J Lab Physicians 5: 1–4.

21. World Health Organization (2011) MDR-TB & XDR-TB 2011 progress report. Geneva: World Health Organization.

22. SteingartKR, SohnH, SchillerI, KlodaLA, BoehmeCC, et al. (2013) Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1: CD009593.

23. BoehmeCC, NabetaP, HillemannD, NicolMP, ShenaiS, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005–1015.

24. BoehmeCC, NicolMP, NabetaP, MichaelJS, GotuzzoE, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495–1505.

25. RaizadaN, SachdevaKS, SreenivasA, VaderaB, GuptaRS, et al. (2014) Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India. PLoS ONE 9: e89301.

26. MenziesNAN, CohenTT, LinH-HH, MurrayMM, SalomonJAJ (2012) Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 9: e1001347.

27. Central TB Division Directorate General of Health Services (2014) TB India 2014. Revised National TB Control Programme. New Delhi: Central TB Division Directorate General of Health Services.

28. DyeC, GarnettGP, SleemanK, WilliamsBG (1998) Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352: 1886–1891.

29. DowdyDW, BasuS, AndrewsJR (2013) Is passive diagnosis enough?: the impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med 187: 543–551.

30. DrobniewskiFAF, PozniakALA (1996) Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Br J Hosp Med (Lond) 56: 204–208.

31. PaiM, DasJ (2013) Management of tuberculosis in India: time for a deeper dive into quality? Natl Med J India 377: 1495–1505.

32. Montagu DD, Anglemyer A, Tiwari M, Drasser K, Rutherford GW, et al.. (2011) Private versus public strategies for health service provision for improving health outcomes in resource-limited settings. San Francisco: Global Health Sciences, University of California, San Francisco.

33. AchantaS, JajuJ, KumarAMV, NagarajaSB, ShamraoSRM, et al. (2012) Tuberculosis management practices by private practitioners in Andhra Pradesh, India. PLoS ONE 8: e71119.

34. EspinalMA, KimSJ, SuarezPG, KamKM, KhomenkoAG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosistreatment outcomes in 6 countries. JAMA 283: 2537–2545.

35. BroydenCG (1970) The convergence of a class of double-rank minimization algorithms 1. General considerations. IMA J Appl Math 6: 76–90.

36. KhanMS, KhanS, Godfrey-FaussettP (2009) Default during TB diagnosis: quantifying the problem. Trop Med Int Health 14: 1437–1441.

37. World Health Organization (2014) WHO monitoring of Xpert MTB/RIF roll-out. Available: http://who.int/tb/laboratory/mtbrifrollout. Accessed 9 Jun 2014.

38. SudhinarasetM, IngramM, LofthouseHK, MontaguD (2013) What is the role of informal healthcare providers in developing countries? A systematic review. PLoS ONE 8: e54978.

39. CaoY, GillespieDT, PetzoldLR (2007) Adaptive explicit-implicit tau-leaping method with automatic tau selection. J Chem Phys 126: 224101.

40. BlowerSM, DowlatabadiH (1994) Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 62: 229–243.

41. R Development Core Team (2010) R: a language and environment for statistical computing, version 2.12. Vienna: R Foundation for Statistical Computing.

42. KayM (2013) Private firms form initiative to offer accurate and affordable TB tests. BMJ 346: f2161.

43. SunAY, PaiM, SaljeH, SatyanarayanaS, DeoS, et al. (2013) Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in southeast Asia. Am J Epidemiol 178: 1740–1749.

44. PaiM, YadavP, AnupindiR (2014) Tuberculosis control needs a complete and patient-centric solution. Lancet Glob Health 2: e189–e190.

45. World Bank (2013) Data: India. Available: http://data.worldbank.org/country/india. Accessed 5 February 2013.

46. Joint United Nations Programme on HIV/AIDS (2013) UNAIDS report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS.

47. TiemersmaEW, van der WerfMJ, BorgdorffMW, WilliamsBG, NagelkerkeNJD (2011) Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE 6: e17601.

48. HillemannD, Ruesch-GerdesS, BoehmeC, RichterE (2011) Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol 49: 1202–1205.

49. CohenT, SommersB, MurrayM (2003) The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 3: 13–21.

50. CorbettEL, WattCJ, WalkerN, MaherD, WilliamsBG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009–1021.

51. GetahunH, HarringtonM, O'BrienR, NunnP (2007) Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369: 2042–2049.

52. VynnyckyE, FinePE (1997) The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 119: 183–201.

53. DaleyCL, SmallPM, SchecterGF, SchoolnikGK, McAdamRA, et al. (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 326: 231–235.

54. BehrMA, WarrenSA, SalamonH, HopewellPC, de LeonAP, et al. (1999) Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 353: 444–449.

55. LewW, PaiM, OxladeO, MartinD, MenziesD (2008) Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149: 123–134.

56. HorsburghCR, O'DonnellM, ChambleeS, MorelandJL, JohnsonJ, et al. (2010) Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 182: 420–425.